{"id":"NCT03805100","sponsor":"Xbrane Biopharma AB","briefTitle":"Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD","officialTitle":"A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-19","primaryCompletion":"2021-05-11","completion":"2021-11-11","firstPosted":"2019-01-15","resultsPosted":"2023-11-13","lastUpdate":"2023-11-13"},"enrollment":582,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Degeneration"],"interventions":[{"type":"BIOLOGICAL","name":"Ranibizumab","otherNames":[]}],"arms":[{"label":"Xlucane","type":"EXPERIMENTAL"},{"label":"Lucentis","type":"ACTIVE_COMPARATOR"}],"summary":"The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).","primaryOutcome":{"measure":"Change in Best Corrected Visual Acuity (BCVA)","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"Xlucane (Proposed Ranibizumab Biosimilar)","deltaMin":4.57,"sd":null},{"arm":"Lucentis (Ranibizumab)","deltaMin":6.37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":32},"locations":{"siteCount":102,"countries":["United States","Bulgaria","Czechia","Estonia","Hungary","India","Israel","Latvia","Lithuania","Poland","Romania","Russia","Slovakia","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":292},"commonTop":["Conjunctival Haemorrhage","Hypertension"]}}